Reassessing therapeutic antibodies for neglected and tropical diseases
In the past two decades there has been a significant expansion in the number of new therapeutic monoclonal antibodies (mAbs) that are approved by regulators. The discovery of these new medicines has been driven primarily by new approaches in inflammatory diseases and oncology, especially in immuno-o...
Gespeichert in:
| Veröffentlicht in: | PLoS neglected tropical diseases 2020-01, Vol.14 (1), p.e0007860 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | e0007860 |
| container_title | PLoS neglected tropical diseases |
| container_volume | 14 |
| creator | Hooft van Huijsduijnen, Rob Kojima, Somei Carter, Dee Okabe, Hisafumi Sato, Akihide Akahata, Wataru Wells, Timothy N C Katsuno, Kei |
| description | In the past two decades there has been a significant expansion in the number of new therapeutic monoclonal antibodies (mAbs) that are approved by regulators. The discovery of these new medicines has been driven primarily by new approaches in inflammatory diseases and oncology, especially in immuno-oncology. Other recent successes have included new antibodies for use in viral diseases, including HIV. The perception of very high costs associated with mAbs has led to the assumption that they play no role in prophylaxis for diseases of poverty. However, improvements in antibody-expression yields and manufacturing processes indicate this is a cost-effective option for providing protection from many types of infection that should be revisited. Recent technology developments also indicate that several months of protection could be achieved with a single dose. Moreover, new methods in B cell sorting now enable the systematic identification of high-quality antibodies from humanized mice, or patients. This Review discusses the potential for passive immunization against schistosomiasis, fungal infections, dengue, and other neglected diseases. |
| doi_str_mv | 10.1371/journal.pntd.0007860 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_2460989299</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_f943fdcc8ea44d97886eddaabf3dcef9</doaj_id><sourcerecordid>2460989299</sourcerecordid><originalsourceid>FETCH-LOGICAL-c577t-3f3b8aab0b0fc6938f05d527dee29ba37d7d5a0ba72cac782030c1ff0faa783a3</originalsourceid><addsrcrecordid>eNptUk1r3DAUNKWl-Wj_QWkNveSym2fLsqRLoYSkDQQKoT2LZ-lpo8VruZId6L-vNuuEpPQk8d7MaEZMUXyoYF0xUZ1vwxwH7NfjMNk1AAjZwqviuFKMr2rB-Otn96PiJKUtAFdcVm-LI1YppVrFj4urW8KUKCU_bMrpjiKONE_elDhMvgvWUypdiOVAm57MRDYvbDnFMHqDfWl9ynxK74o3DvtE75fztPh1dfnz4vvq5se364uvNyvDhZhWzLFOInbQgTOtYtIBt7wWlqhWHTJhheUIHYraoBGyBgamcg4copAM2Wnx6aA79iHp5QuSrpsWlFS1UhlxfUDYgFs9Rr_D-EcH9PphEOJGY8wBe9JONcxZYyRh01glpGzJ2mzPMWvI7bW-LK_N3Y7ybJgi9i9EX24Gf6c34V63SlWKN1ngbBGI4fdMadI7nwz1PQ4U5uybcQAlGLAM_fwP9P_pmgPKxJBSJPdkpgK9r8UjS-9roZdaZNrH50GeSI89YH8B2vS5Kw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2460989299</pqid></control><display><type>article</type><title>Reassessing therapeutic antibodies for neglected and tropical diseases</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Hooft van Huijsduijnen, Rob ; Kojima, Somei ; Carter, Dee ; Okabe, Hisafumi ; Sato, Akihide ; Akahata, Wataru ; Wells, Timothy N C ; Katsuno, Kei</creator><contributor>Roeltgen, Katharina</contributor><creatorcontrib>Hooft van Huijsduijnen, Rob ; Kojima, Somei ; Carter, Dee ; Okabe, Hisafumi ; Sato, Akihide ; Akahata, Wataru ; Wells, Timothy N C ; Katsuno, Kei ; Roeltgen, Katharina</creatorcontrib><description>In the past two decades there has been a significant expansion in the number of new therapeutic monoclonal antibodies (mAbs) that are approved by regulators. The discovery of these new medicines has been driven primarily by new approaches in inflammatory diseases and oncology, especially in immuno-oncology. Other recent successes have included new antibodies for use in viral diseases, including HIV. The perception of very high costs associated with mAbs has led to the assumption that they play no role in prophylaxis for diseases of poverty. However, improvements in antibody-expression yields and manufacturing processes indicate this is a cost-effective option for providing protection from many types of infection that should be revisited. Recent technology developments also indicate that several months of protection could be achieved with a single dose. Moreover, new methods in B cell sorting now enable the systematic identification of high-quality antibodies from humanized mice, or patients. This Review discusses the potential for passive immunization against schistosomiasis, fungal infections, dengue, and other neglected diseases.</description><identifier>ISSN: 1935-2735</identifier><identifier>ISSN: 1935-2727</identifier><identifier>EISSN: 1935-2735</identifier><identifier>DOI: 10.1371/journal.pntd.0007860</identifier><identifier>PMID: 31999695</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Animals ; Antibodies ; Antibodies, Monoclonal - pharmacology ; Biology and Life Sciences ; Cancer immunotherapy ; Costs ; Dengue ; Dengue - drug therapy ; Dengue fever ; Disease prophylaxis ; Drug Development ; Drug dosages ; FDA approval ; HIV ; Human diseases ; Human immunodeficiency virus ; Humans ; Immunization ; Immunization, Passive ; Infections ; Infectious diseases ; Inflammatory diseases ; Malaria ; Manufacturing industry ; Medicine and Health Sciences ; Mice ; Monoclonal antibodies ; Mycoses - drug therapy ; Neglected Diseases - drug therapy ; Oncology ; Peptides ; Poverty ; Prophylaxis ; Protection ; Proteins ; Regulators ; Research and Analysis Methods ; Respiratory syncytial virus ; Review ; Rheumatoid arthritis ; Schistosomiasis ; Schistosomiasis - drug therapy ; Success ; Tropical climate ; Tropical diseases ; Tropical Medicine ; Tumor necrosis factor-TNF ; Vector-borne diseases ; Viral diseases ; Viral infections ; Viroses</subject><ispartof>PLoS neglected tropical diseases, 2020-01, Vol.14 (1), p.e0007860</ispartof><rights>2020 Hooft van Huijsduijnen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Hooft van Huijsduijnen et al 2020 Hooft van Huijsduijnen et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c577t-3f3b8aab0b0fc6938f05d527dee29ba37d7d5a0ba72cac782030c1ff0faa783a3</citedby><cites>FETCH-LOGICAL-c577t-3f3b8aab0b0fc6938f05d527dee29ba37d7d5a0ba72cac782030c1ff0faa783a3</cites><orcidid>0000-0002-4638-0059 ; 0000-0002-2261-9424</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991954/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991954/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2100,2926,23864,27922,27923,53789,53791,79370,79371</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31999695$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Roeltgen, Katharina</contributor><creatorcontrib>Hooft van Huijsduijnen, Rob</creatorcontrib><creatorcontrib>Kojima, Somei</creatorcontrib><creatorcontrib>Carter, Dee</creatorcontrib><creatorcontrib>Okabe, Hisafumi</creatorcontrib><creatorcontrib>Sato, Akihide</creatorcontrib><creatorcontrib>Akahata, Wataru</creatorcontrib><creatorcontrib>Wells, Timothy N C</creatorcontrib><creatorcontrib>Katsuno, Kei</creatorcontrib><title>Reassessing therapeutic antibodies for neglected and tropical diseases</title><title>PLoS neglected tropical diseases</title><addtitle>PLoS Negl Trop Dis</addtitle><description>In the past two decades there has been a significant expansion in the number of new therapeutic monoclonal antibodies (mAbs) that are approved by regulators. The discovery of these new medicines has been driven primarily by new approaches in inflammatory diseases and oncology, especially in immuno-oncology. Other recent successes have included new antibodies for use in viral diseases, including HIV. The perception of very high costs associated with mAbs has led to the assumption that they play no role in prophylaxis for diseases of poverty. However, improvements in antibody-expression yields and manufacturing processes indicate this is a cost-effective option for providing protection from many types of infection that should be revisited. Recent technology developments also indicate that several months of protection could be achieved with a single dose. Moreover, new methods in B cell sorting now enable the systematic identification of high-quality antibodies from humanized mice, or patients. This Review discusses the potential for passive immunization against schistosomiasis, fungal infections, dengue, and other neglected diseases.</description><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Biology and Life Sciences</subject><subject>Cancer immunotherapy</subject><subject>Costs</subject><subject>Dengue</subject><subject>Dengue - drug therapy</subject><subject>Dengue fever</subject><subject>Disease prophylaxis</subject><subject>Drug Development</subject><subject>Drug dosages</subject><subject>FDA approval</subject><subject>HIV</subject><subject>Human diseases</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization, Passive</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Inflammatory diseases</subject><subject>Malaria</subject><subject>Manufacturing industry</subject><subject>Medicine and Health Sciences</subject><subject>Mice</subject><subject>Monoclonal antibodies</subject><subject>Mycoses - drug therapy</subject><subject>Neglected Diseases - drug therapy</subject><subject>Oncology</subject><subject>Peptides</subject><subject>Poverty</subject><subject>Prophylaxis</subject><subject>Protection</subject><subject>Proteins</subject><subject>Regulators</subject><subject>Research and Analysis Methods</subject><subject>Respiratory syncytial virus</subject><subject>Review</subject><subject>Rheumatoid arthritis</subject><subject>Schistosomiasis</subject><subject>Schistosomiasis - drug therapy</subject><subject>Success</subject><subject>Tropical climate</subject><subject>Tropical diseases</subject><subject>Tropical Medicine</subject><subject>Tumor necrosis factor-TNF</subject><subject>Vector-borne diseases</subject><subject>Viral diseases</subject><subject>Viral infections</subject><subject>Viroses</subject><issn>1935-2735</issn><issn>1935-2727</issn><issn>1935-2735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNptUk1r3DAUNKWl-Wj_QWkNveSym2fLsqRLoYSkDQQKoT2LZ-lpo8VruZId6L-vNuuEpPQk8d7MaEZMUXyoYF0xUZ1vwxwH7NfjMNk1AAjZwqviuFKMr2rB-Otn96PiJKUtAFdcVm-LI1YppVrFj4urW8KUKCU_bMrpjiKONE_elDhMvgvWUypdiOVAm57MRDYvbDnFMHqDfWl9ynxK74o3DvtE75fztPh1dfnz4vvq5se364uvNyvDhZhWzLFOInbQgTOtYtIBt7wWlqhWHTJhheUIHYraoBGyBgamcg4copAM2Wnx6aA79iHp5QuSrpsWlFS1UhlxfUDYgFs9Rr_D-EcH9PphEOJGY8wBe9JONcxZYyRh01glpGzJ2mzPMWvI7bW-LK_N3Y7ybJgi9i9EX24Gf6c34V63SlWKN1ngbBGI4fdMadI7nwz1PQ4U5uybcQAlGLAM_fwP9P_pmgPKxJBSJPdkpgK9r8UjS-9roZdaZNrH50GeSI89YH8B2vS5Kw</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Hooft van Huijsduijnen, Rob</creator><creator>Kojima, Somei</creator><creator>Carter, Dee</creator><creator>Okabe, Hisafumi</creator><creator>Sato, Akihide</creator><creator>Akahata, Wataru</creator><creator>Wells, Timothy N C</creator><creator>Katsuno, Kei</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7SS</scope><scope>7T2</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>F1W</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>H95</scope><scope>H97</scope><scope>K9.</scope><scope>L.G</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4638-0059</orcidid><orcidid>https://orcid.org/0000-0002-2261-9424</orcidid></search><sort><creationdate>20200101</creationdate><title>Reassessing therapeutic antibodies for neglected and tropical diseases</title><author>Hooft van Huijsduijnen, Rob ; Kojima, Somei ; Carter, Dee ; Okabe, Hisafumi ; Sato, Akihide ; Akahata, Wataru ; Wells, Timothy N C ; Katsuno, Kei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c577t-3f3b8aab0b0fc6938f05d527dee29ba37d7d5a0ba72cac782030c1ff0faa783a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Biology and Life Sciences</topic><topic>Cancer immunotherapy</topic><topic>Costs</topic><topic>Dengue</topic><topic>Dengue - drug therapy</topic><topic>Dengue fever</topic><topic>Disease prophylaxis</topic><topic>Drug Development</topic><topic>Drug dosages</topic><topic>FDA approval</topic><topic>HIV</topic><topic>Human diseases</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization, Passive</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Inflammatory diseases</topic><topic>Malaria</topic><topic>Manufacturing industry</topic><topic>Medicine and Health Sciences</topic><topic>Mice</topic><topic>Monoclonal antibodies</topic><topic>Mycoses - drug therapy</topic><topic>Neglected Diseases - drug therapy</topic><topic>Oncology</topic><topic>Peptides</topic><topic>Poverty</topic><topic>Prophylaxis</topic><topic>Protection</topic><topic>Proteins</topic><topic>Regulators</topic><topic>Research and Analysis Methods</topic><topic>Respiratory syncytial virus</topic><topic>Review</topic><topic>Rheumatoid arthritis</topic><topic>Schistosomiasis</topic><topic>Schistosomiasis - drug therapy</topic><topic>Success</topic><topic>Tropical climate</topic><topic>Tropical diseases</topic><topic>Tropical Medicine</topic><topic>Tumor necrosis factor-TNF</topic><topic>Vector-borne diseases</topic><topic>Viral diseases</topic><topic>Viral infections</topic><topic>Viroses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hooft van Huijsduijnen, Rob</creatorcontrib><creatorcontrib>Kojima, Somei</creatorcontrib><creatorcontrib>Carter, Dee</creatorcontrib><creatorcontrib>Okabe, Hisafumi</creatorcontrib><creatorcontrib>Sato, Akihide</creatorcontrib><creatorcontrib>Akahata, Wataru</creatorcontrib><creatorcontrib>Wells, Timothy N C</creatorcontrib><creatorcontrib>Katsuno, Kei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PLoS neglected tropical diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hooft van Huijsduijnen, Rob</au><au>Kojima, Somei</au><au>Carter, Dee</au><au>Okabe, Hisafumi</au><au>Sato, Akihide</au><au>Akahata, Wataru</au><au>Wells, Timothy N C</au><au>Katsuno, Kei</au><au>Roeltgen, Katharina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reassessing therapeutic antibodies for neglected and tropical diseases</atitle><jtitle>PLoS neglected tropical diseases</jtitle><addtitle>PLoS Negl Trop Dis</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>14</volume><issue>1</issue><spage>e0007860</spage><pages>e0007860-</pages><issn>1935-2735</issn><issn>1935-2727</issn><eissn>1935-2735</eissn><abstract>In the past two decades there has been a significant expansion in the number of new therapeutic monoclonal antibodies (mAbs) that are approved by regulators. The discovery of these new medicines has been driven primarily by new approaches in inflammatory diseases and oncology, especially in immuno-oncology. Other recent successes have included new antibodies for use in viral diseases, including HIV. The perception of very high costs associated with mAbs has led to the assumption that they play no role in prophylaxis for diseases of poverty. However, improvements in antibody-expression yields and manufacturing processes indicate this is a cost-effective option for providing protection from many types of infection that should be revisited. Recent technology developments also indicate that several months of protection could be achieved with a single dose. Moreover, new methods in B cell sorting now enable the systematic identification of high-quality antibodies from humanized mice, or patients. This Review discusses the potential for passive immunization against schistosomiasis, fungal infections, dengue, and other neglected diseases.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>31999695</pmid><doi>10.1371/journal.pntd.0007860</doi><orcidid>https://orcid.org/0000-0002-4638-0059</orcidid><orcidid>https://orcid.org/0000-0002-2261-9424</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1935-2735 |
| ispartof | PLoS neglected tropical diseases, 2020-01, Vol.14 (1), p.e0007860 |
| issn | 1935-2735 1935-2727 1935-2735 |
| language | eng |
| recordid | cdi_plos_journals_2460989299 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Animals Antibodies Antibodies, Monoclonal - pharmacology Biology and Life Sciences Cancer immunotherapy Costs Dengue Dengue - drug therapy Dengue fever Disease prophylaxis Drug Development Drug dosages FDA approval HIV Human diseases Human immunodeficiency virus Humans Immunization Immunization, Passive Infections Infectious diseases Inflammatory diseases Malaria Manufacturing industry Medicine and Health Sciences Mice Monoclonal antibodies Mycoses - drug therapy Neglected Diseases - drug therapy Oncology Peptides Poverty Prophylaxis Protection Proteins Regulators Research and Analysis Methods Respiratory syncytial virus Review Rheumatoid arthritis Schistosomiasis Schistosomiasis - drug therapy Success Tropical climate Tropical diseases Tropical Medicine Tumor necrosis factor-TNF Vector-borne diseases Viral diseases Viral infections Viroses |
| title | Reassessing therapeutic antibodies for neglected and tropical diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T15%3A02%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reassessing%20therapeutic%20antibodies%20for%20neglected%20and%20tropical%20diseases&rft.jtitle=PLoS%20neglected%20tropical%20diseases&rft.au=Hooft%20van%20Huijsduijnen,%20Rob&rft.date=2020-01-01&rft.volume=14&rft.issue=1&rft.spage=e0007860&rft.pages=e0007860-&rft.issn=1935-2735&rft.eissn=1935-2735&rft_id=info:doi/10.1371/journal.pntd.0007860&rft_dat=%3Cproquest_plos_%3E2460989299%3C/proquest_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2460989299&rft_id=info:pmid/31999695&rft_doaj_id=oai_doaj_org_article_f943fdcc8ea44d97886eddaabf3dcef9&rfr_iscdi=true |